This study is looking at how well a medication called setmelanotide works to treat obesity in one patient with Pseudohypoparathyroidism Type 1a (PHP1a). PHP1a is a rare genetic condition that can cause various health issues, including obesity. Researchers believe setmelanotide might help by improving how the body's cells respond to certain signals related to weight. To join, you must have PHP1a confirmed by a specific genetic test (GNAS mutation) and have your diabetes and high cholesterol (dyslipidemia) well-managed. The study will give setmelanotide as a daily injection for six months, starting at a lower dose and increasing it if tolerated. The main goal is to see if the patient loses 5% or more of their body weight during this time. The current status of this study is unclear.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It is an open-label study, so both you and the study team will know you are receiving setmelanotide. This study plans to enroll one participant.

What's involved

You would receive daily injections of setmelanotide for six months. There will be a visit at two weeks to adjust the medication dose.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at six months, indicating follow-up for at least that duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.